Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

U.S. Pulmonary Arterial Hypertension Markets

Published by: Frost & Sullivan

Published: Dec. 12, 2006


Table of Contents



1. Executive Summary

      1. Executive Summary

              1. Executive Summary



2. Total U.S. Pulmonary Hypertension Markets

      1. Market Overview

              1. Introduction

              2. Market Segmentation

              3. Research Methodology

      2. Market Forecasts

              1. Patient Forecasts

              2. Pricing Forecasts

              3. Revenue Forecasts

      3. Competitive Analysis

              1. Competitive Structure

              2. Market Share Analysis

              3. Product Pipeline



3. U.S. Class I Pulmonary Arterial Hypertension Market

      1. Market Overview

              1. Introduction

              2. Market Engineering Measurements

      2. Market Forecasts

              1. Patient Forecasts

              2. Pricing Forecasts

              3. Revenue Forecasts

      3. Competitive Analysis

              1. Competitive Structure

              2. Market Share Analysis



4. U.S. Class II Pulmonary Arterial Hypertension Market

      1. Market Overview

              1. Introduction

              2. Market Engineering Measurements

      2. Market Forecasts

              1. Patient Forecasts

              2. Pricing Forecasts

              3. Revenue Forecasts

      3. Competitive Analysis

              1. Competitive Structure

              2. Market Share Analysis



5. U.S. Class III Pulmonary Arterial Hypertension Market

      1. Market Overview

              1. Introduction

              2. Market Engineering Measurements

      2. Market Forecasts

              1. Patient Forecasts

              2. Pricing Forecasts

              3. Revenue Forecasts

      3. Competitive Analysis

              1. Competitive Structure

              2. Market Share Analysis



6. U.S. Class IV Pulmonary Arterial Hypertension Market

      1. Market Overview

              1. Introduction

              2. Market Engineering Measurements

      2. Market Forecasts

              1. Patient Forecasts

              2. Pricing Forecasts

              3. Revenue Forecasts

      3. Competitive Analysis

              1. Competitive Structure

              2. Market Share Analysis



7. Decision Support Databases

      1. Disease Incidence

              1. HIV Prevalence

              2. AIDS Incidence

              3. Coronary Heart Disease Prevalence

              4. Hypertension Prevalence


List of Figures


Chapter 2

  • Total Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
  • Total Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Revenue Market Share by PAH Class (U.S.), 2003-2013
  • Total Pulmonary Arterial Hypertension Market: Patient Market Share by PAH Class (U.S.), 2003-2013

Chapter 3

  • Class I Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
  • Class I Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
  • Class I Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
  • Class I Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
  • Class I Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
  • Class I Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 4

  • Class II Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
  • Class II Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
  • Class II Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
  • Class II Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
  • Class II Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
  • Class II Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 5

  • Class III Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
  • Class III Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
  • Class III Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
  • Class III Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
  • Class III Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
  • Class III Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 6

  • Class IV Pulmonary Arterial Hypertension Market: Patient Forecasts (U.S.), 2003-2013
  • Class IV Pulmonary Arterial Hypertension Market: Pricing Forecasts (U.S.), 2003-2013
  • Class IV Pulmonary Arterial Hypertension Market: Revenue Forecasts (U.S.), 2003-2013
  • Class IV Pulmonary Arterial Hypertension Market: Competitive Structure (U.S.), 2006
  • Class IV Pulmonary Arterial Hypertension Market: Revenue Market Share by Product (U.S.), 2003-2013
  • Class IV Pulmonary Arterial Hypertension Market: Revenue Market Share by Product Type (U.S.), 2003-2013

Chapter 7

  • Decision Support Database: Prevalence of HIV in ’000 (World), 1999-2006
  • Decision Support Database: AIDS Reported Cases (World), 1999-2006
  • Decision Support Database: Prevalence of Coronary Heart Disease in Million (World), 1999-2006
  • Decision Support Database: Prevalence of Hypertension in Million (World), 1999-2006

    Abstract

    Research Overview

    This Frost & Sullivan research service entitled U.S. Pulmonary Arterial Hypertension Markets provides a detailed analysis of the competitive structure, market forecasts, and market share analysis. In this research, Frost & Sullivan's expert analysts thoroughly examine the class I, class II, class III, and class IV PAH therapy markets.

    Market Sectors

    Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
    • Total U.S. PAH therapy
    • Class I PAH therapy
    • Class II PAH therapy
    • Class III PAH therapy
    • Class IV PAH therapy
    Market Overview

    "Big Pharma" and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets

    The U.S. pulmonary arterial hypertension (PAH) markets have been growing due to the launch of new therapies as well as keen interest shown by "Big Pharma" and biotechnology companies. A small patient population notwithstanding, the market is expected to grow rapidly. "The development of a strong clinical pipeline with two major launches in 2007, and improvement in diagnosis rates are likely to drive market growth," says the analyst of this research service.

    The number of treatment options available for this condition has grown considerably over the past few years with new therapies expected. The granting of orphan drug status has encouraged the development of drugs, which would have been cost-prohibitive and unprofitable under normal circumstances. "Big Pharma" companies are focusing on this therapeutic area despite the orphan drug status. With increasing awareness of the disease and introduction of better treatment options, diagnosis rates are expected to rise further.

    In-licensing Deals and Mergers and Acquisitions Spur Strong Growth

    An increase in in-licensing and M&A deals in the PAH markets is also leveraging growth. "The market has drawn interest from "Big Pharma" and biotechnology companies partly due to the high reimbursement rates and average revenue per patient," states the analyst. Therefore, companies are looking to enter into the market through mergers and acquisitions or licensing of clinical stage products.

    The key competitive factors include efficacy, convenience of dosing, and side effect profiles of therapies. The progression of PAH is rapid and the mortality rates are extremely high with most patients surviving for less than 3-4 years post diagnosis. Hence, the efficacy of a drug to slow down the progression of the disease, coupled with convenience of dosing is the prime competitive factor.

    Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008